Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARS-2
- Development stage
- Unknown
- Lead developer
- ARS Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
ARS-2 is an investigational intranasal epinephrine spray being developed by ARS Pharmaceuticals for the acute treatment of symptoms in adults with chronic spontaneous urticaria whose disease remains uncontrolled on standard therapy. ARS-2 delivers epinephrine via the nasal mucosa to rapidly counteract mast cell–mediated type I hypersensitivity reactions and reduce hives and pruritus during urticaria flares, offering a needle-free alternative to injectable epinephrine. It is being evaluated in randomized, double-blind, placebo-controlled outpatient studies at doses around 0.5–1 mg for its efficacy, onset of action, and safety in this population.[1][3][5][8]
- Other names
- epinephrine nasal spray ARS-2
Beyond the preview
Go deeper on ARS-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARS-2.